AbbVie Inc (NYSE:ABBV)., a leading biopharmaceutical company, stands at a critical juncture as it navigates the loss of ...

Leerink Partners analyst David Risinger has reiterated their bullish stance on ABBV stock, giving a Buy rating yesterday.Stay Ahead of the ...

AbCellera (ABCL) announced that it has expanded its existing collaboration with AbbVie (ABBV) to include the discovery of T-cell engagers in ...

AbbVie's strong financials and potential for cash flow make it a valuable investment, despite risks from patent expirations.

AbbVie will commit less capital towards experimental medicines for psychiatric disease, CEO Robert Michael said at an ...

These acquisitions aim to enhance AbbVie's pipeline in immunology and inflammation, neuropsychiatry, oncology, and aesthetics. Lastly, AbbVie reported positive results from its Phase 3 TEMPO-2 ...

These acquisitions aim to enhance AbbVie's pipeline in immunology and inflammation, neuropsychiatry, oncology, and aesthetics. Lastly, AbbVie reported positive results from its Phase 3 TEMPO-2 trial ...

NORTH CHICAGO, Ill. and SHANGHAI, Jan. 13, 2025 /PRNewswire/ -- AbbVie (NYSE: ABBV) and Simcere Zaiming, a subsidiary of Simcere Pharmaceutical Group Ltd (HKEX: 2096) today announced an option to ...

SHANGHAI and NORTH CHICAGO, Ill., Jan. 13, 2025 /PRNewswire/ -- Simcere Zaiming, a subsidiary of Simcere Pharmaceutical Group Ltd (HKEX: 2096) and AbbVie Inc. (NYSE: ABBV) today announced an option to ...

trispecific antibody that targets GPRC5D, BCMA, and CD3, developed independently by Simcere Zaiming using their T-cell engager polyspecific antibody technology platform. This molecule features a ...

SIM0500 is a humanized trispecific antibody that targets GPRC5D, BCMA, and CD3, developed independently by Simcere Zaiming using their T-cell engager polyspecific antibody technology platform.